The global cancer diagnostics market was valued at around USD 15.13 billion in 2023 and is projected to grow steadily, reaching about USD 31 billion by 2032. This reflects a healthy annual growth rate of 8.5%. In 2023, North America led the way, accounting for nearly 36% of the market share.
Cancer diagnostics play a critical role in identifying and classifying different types of cancer using methods like immunohistochemistry, in-situ hybridization, and others. With cancer cases rising worldwide, there’s a growing demand for advanced diagnostic tools that can detect the disease early. Thes World Health Organization (WHO) estimates that new cancer cases will reach 35 million by 2050—a significant jump from 20 million in 2022.
To keep up with this demand, major companies are putting more focus on research and development. For instance, in February 2023, F. Hoffmann-La Roche Ltd expanded its partnership with Janssen Biotech Inc. to push forward innovation in companion diagnostics. Their work includes developing cutting-edge tools like next-generation sequencing, digital pathology, PCR, and immunoassays.
Get a Free Sample Research PDF:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cancer-diagnostics-market-110706
Market Segmentation:
By product type, the market includes instruments, consumables, and services. Instruments such as imaging systems and biopsy devices are widely used, while consumables like reagents and assay kits are in continuous demand due to their role in daily diagnostic procedures. Services related to genetic and biomarker testing are also growing in prominence.
When segmented by technology, the Cancer Diagnostics Market comprises imaging techniques (MRI, CT, PET), immunoassays, flow cytometry, and molecular diagnostics, among others. Imaging remains a cornerstone in cancer detection, whereas molecular diagnostics are gaining popularity for their precision and potential in personalized treatment approaches.
In terms of application, the Cancer Diagnostics Market covers a wide range of cancers including breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. Breast and lung cancer diagnostics account for the largest market share due to their high prevalence globally.
By end-user, hospitals, diagnostic laboratories, and academic research institutions are the key segments. Hospitals dominate due to their comprehensive diagnostic capabilities, while specialized laboratories and academic settings contribute significantly to R&D and testing innovations in cancer diagnostics.
List Of Key Cancer Diagnostics Market Players Profiled In This Report:
Hoffmann-La Roche Ltd (Switzerland)
Thermo Fisher Scientific Inc. (U.S.)
Abbott (U.S.)
Illumina, Inc. (U.S.)
GE Healthcare (U.S.)
BD (U.S.)
bioMérieux SA (France)
Myriad Genetics, Inc (U.S.)
Bio-Rad Laboratories, Inc. (U.S.)
QIAGEN (Germany)
Market Growth:
The Cancer Diagnostics Market is experiencing robust growth due to the rising global incidence of cancer, growing awareness among patients, and increased healthcare spending. Technological advancements in diagnostic imaging, molecular diagnostics, and biomarker testing are significantly boosting market revenue. Moreover, government initiatives aimed at cancer screening and early detection programs are fueling the expansion of this market. The growing geriatric population, which is more susceptible to various types of cancer, further contributes to the escalating demand for diagnostic solutions.
Restraining Factors:
Despite its positive growth trajectory, the Cancer Diagnostics Market faces certain challenges. High costs associated with advanced diagnostic tools and procedures limit accessibility, particularly in low- and middle-income countries. Additionally, the lack of skilled professionals and inadequate infrastructure in emerging regions hinder market penetration. There are also concerns related to the accuracy of certain diagnostic techniques and the regulatory hurdles that may delay product approvals and market entry.
Regional Analysis:
Geographically, North America holds the largest share in the Cancer Diagnostics Market, supported by advanced healthcare infrastructure, high healthcare expenditure, and a well-established diagnostics sector. Europe follows closely, with countries like Germany, the UK, and France showing strong demand for innovative diagnostic solutions. The Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by a growing patient pool, rising awareness, and government efforts to enhance healthcare access. Meanwhile, Latin America and the Middle East & Africa show moderate growth due to improving medical facilities and increasing investment in healthcare diagnostics.
Key Industry Developments:
In 2023 and 2024, the Cancer Diagnostics Market witnessed major advancements in liquid biopsy technologies, ctDNA and CTC testing, and AI-based diagnostic imaging. Companies increasingly focused on developing non-invasive, precise, and early detection tools, aligning with the growing demand for personalized medicine. Strategic collaborations, acquisitions, and new product launches further expanded diagnostic capabilities, while technological innovation drove growth across both developed and emerging markets.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free)
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com